FNCH Logo

Finch Therapeutics Group, Inc. (FNCH) 

NASDAQ
Market Cap
$18.32M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
535 of 774
Rank in Industry
287 of 432

Largest Insider Buys in Sector

FNCH Stock Price History Chart

FNCH Stock Performance

About Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism …

Insider Activity of Finch Therapeutics Group, Inc.

Over the last 12 months, insiders at Finch Therapeutics Group, Inc. have bought $0 and sold $26,597 worth of Finch Therapeutics Group, Inc. stock.

On average, over the past 5 years, insiders at Finch Therapeutics Group, Inc. have bought $10.47M and sold $12,820 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,010 shares for transaction amount of $1,353 was made by Graf Susan E (director) on 2023‑06‑09.

List of Insider Buy and Sell Transactions, Finch Therapeutics Group, Inc.

2024-03-28Saledirector
8,242
0.5089%
$2.58$21,246-5.58%
2023-11-22Saledirector
1,470
0.0901%
$3.64$5,351-24.59%
2023-06-09Purchasedirector
5,010
0.0003%
$0.27$1,353-54.61%
2023-02-21SaleChief Operating Officer
4,619
0.0097%
$0.38$1,755+29014.17%
2022-10-21SaleChief Operating Officer
3,636
0.0078%
$1.39$5,054-32.44%
2022-10-21SaleChief Business & Legal Officer
3,636
0.0078%
$1.39$5,054-32.44%
2021-12-20Purchasedirector
63,850
0.1713%
$10.18$649,993-73.92%
2021-03-23Purchase
735,294
5.3498%
$17.00$12.5M-19.16%
2021-03-23Purchasedirector
88,235
0.642%
$17.00$1.5M-19.16%
2021-03-23Purchasedirector
882,351
6.4197%
$17.00$15M-19.16%
2021-03-23Purchasedirector
102,941
0.749%
$17.00$1.75M-19.16%

Insider Historical Profitability

<0.0001%
SMISEK JEFFERY Adirector
0
0%
$11.4112<0.0001%
Crestovo Investor LLC
12641441
787.2559%
$11.4110<0.0001%
Haft Nicholasdirector
4056907
252.6472%
$11.4120<0.0001%
FERRANTE DOMENIC Jdirector
636195
39.6196%
$11.4110<0.0001%
Graf Susan Edirector
5010
0.312%
$11.4110<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.